Singapore markets close in 2 hours 20 minutes
  • Straits Times Index

    3,240.96
    +15.51 (+0.48%)
     
  • Nikkei

    27,574.43
    -111.97 (-0.40%)
     
  • Hang Seng

    19,385.43
    +570.61 (+3.03%)
     
  • FTSE 100

    7,489.19
    -32.20 (-0.43%)
     
  • BTC-USD

    16,817.48
    -174.00 (-1.02%)
     
  • CMC Crypto 200

    394.59
    -7.45 (-1.85%)
     
  • S&P 500

    3,933.92
    -7.34 (-0.19%)
     
  • Dow

    33,597.92
    +1.58 (+0.00%)
     
  • Nasdaq

    10,958.55
    -56.34 (-0.51%)
     
  • Gold

    1,797.30
    -0.70 (-0.04%)
     
  • Crude Oil

    72.80
    +0.79 (+1.10%)
     
  • 10-Yr Bond

    3.4080
    0.0000 (0.00%)
     
  • FTSE Bursa Malaysia

    1,466.98
    +0.10 (+0.01%)
     
  • Jakarta Composite Index

    6,752.47
    -66.29 (-0.97%)
     
  • PSE Index

    6,525.16
    -149.22 (-2.24%)
     

Here's Why This Dividend King Is a Buy

Here's Why This Dividend King Is a Buy

Among the most notable stocks to do so, AbbVie (NYSE: ABBV) is actually trading up 6% on the year. AbbVie is best known as the maker of the top-selling drug in the world, Humira. This stacked lineup of products explains how the drugmaker's net revenue increased 4.5% year over year to $14.6 billion in the second quarter.